New hope for STK11 lung cancer: experimental combo enters trial

NCT ID NCT07017829

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 4 times

Summary

This phase II trial tests whether adding an experimental antibody called GT103 to the immunotherapy drug pembrolizumab can help people with advanced STK11-mutant non-small cell lung cancer. The study enrolls 28 adults whose cancer has worsened despite prior pembrolizumab treatment. Participants receive both drugs intravenously, and researchers track how long the cancer stays under control and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GT103 (a monoclonal antibody) and pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for people with a hard-to-treat form of lung cancer that has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The combination could cause side effects like immune-related inflammation, and it may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    RECRUITING

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.